glp 1 direct to consumer GLP-1 costs rise, but there are ways save on weight-loss drugs Direct Meds GLP-1 Program Report

Wall Street reacts Deutsche Bank analysts saw the deal as a potential catalyst for Lillys growth

If you are a patient at Primary Care Center of Clear Lake and have reached a weight loss plateau while using Wegovy (semaglutide), you may be wondering if switching to Zepbound (tirzepatide) could help you continue your progress

Nutrition, regular hydration, and staying active help speed up results and reduce side effects

monitor thyroid levels Oral Contraceptives : See above Inform Healthcare Providers : Provide complete medication list to Ro provider during assessment Inform all healthcare providers about GLP-1 medication use Who Should NOT Use GLP-1 Weight Loss Medications According to FDA prescribing information: Absolute Contraindications (NEVER use): Personal history of medullary thyroid carcinoma (MTC) Family history of MTC (any family member) Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Family history of MEN 2 (any family member) Known severe hypersensitivity to medication or components Pregnancy Breastfeeding Relative Contraindications (Use only with extreme caution, risk-benefit evaluation): History of pancreatitis Severe gastrointestinal disease: Gastroparesis Inflammatory bowel disease (severe) Chronic diarrhea or constipation Active gallbladder disease Diabetic retinopathy (especially if severe or proliferative) Severe chronic kidney disease (eGFR 30 ml/min/1.73m) History of suicidal ideation or attempts Severe depression or other serious mental health conditions Active eating disorders (anorexia nervosa, bulimia nervosa) Age under 18 years (not approved for pediatric use for weight loss) Reporting Adverse Events and Accessing Complete Safety Information How to Report Side Effects : According to FDA guidance, healthcare providers and patients should report adverse events: FDA MedWatch Program : Phone : 1-800-FDA-1088 Online : www.fda.gov/medwatch What to Report : Serious side effects, unexpected side effects, medication errors, product quality issues Manufacturer Reporting : Eli Lilly (Zepbound): 1-800-545-5979 Novo Nordisk (Wegovy, Ozempic): 1-800-727-6500 Ro Provider Reporting : Always report concerning symptoms to Ro-affiliated provider through secure messaging Provider will evaluate and determine appropriate response Why Reporting Matters : Helps identify previously unknown side effects Contributes to ongoing safety monitoring May lead to updated warnings or prescribing information Protects future patients Accessing Complete Prescribing Information : For comprehensive safety details: FDA Website : Search medication name at www.fda.gov/drugs Manufacturer Websites : Wegovy: www.wegovy.com Zepbound: www.zepbound.com Ozempic: www.ozempic.com Ro Safety Portal : ro.co/safety Prescribing Information : Provided with medication

GLP-1 Receptor Agonist Market Demand, Opportunity, 2026-2034 REPORT DETAILS GLP-1 Receptor Agonist Market Summary The global GLP-1 receptor agonist market size was valued at USD 61.89 billion in 2025

Semaglutide injections contain a synthetic version of the natural hormone GLP-1